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Uday Popat,1 Rima Saliba,1 Rupinderjit Thandi,1 Chitra Hosing,1 Muzaffar Qazilbash,1
Paolo Anderlini,1 Elizabeth Shpall,1 John McMannis,1 Martin Ko¨rbling,1 Amin Alousi,1
Borje Andersson,1 Yago Nieto,1 Partow Kebriaei,1 Issa Khouri,1 Marcos de Lima,1
Donna Weber,2 Sheeba Thomas,2 Michael Wang,2 Roy Jones,1
Richard Champlin,1 Sergio Giralt1Lenalidomide is an agent that has shown great activity in patients with multiple myeloma (MM). However,
studies have suggested that this drug negatively affects subsequent stem cell collection. To investigate
whether lenalidomide impairs stem cell mobilization and collection, we reviewed data for patients with
MM who underwent mobilization with filgrastim. Predictors of mobilization failure were evaluated using lo-
gistic regression analysis. In 26 (9%) of 302 myeloma patients, stem cell mobilization failed. Mobilization failed
in 25% of patients who had previously received lenalidomide, compared with 4% of patients who had not
received lenalidomide (P\.001). In a multivariate analysis, prior lenalidomide use (odds ratio: 5.9; 95% con-
fidence interval [CI]: 2.4-14.3) and mobilization more than 1 year after diagnosis (odds ratio: 4.6; 95% CI: 1.9-
11.1) were significantly associated with failed mobilization. Twenty-one of 26 patients in whom mobilization
with filgrastim failed underwent remobilization with chemotherapy and filgrastim; in 18 (86%) of these 21
patients, stem cells were successfully mobilized and collected. In patients with multiple myeloma, prior lena-
lidomide therapy is associated with failure of stem cell mobilization with filgrastim. Remobilization with che-
motherapy and filgrastim is usually successful in these patients.
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Thalidomide, bortezomib, and lenalidomide are
changing therapeutic paradigms in patients withmulti-
ple myeloma (MM) [1,2]. Used as salvage therapy,
these agents have been highly effective in increasing re-
sponse rates, event-free survival (EFS), and overall sur-
vival (OS) when standard therapies have failed [3-13].
Increasingly, these agents are being used as frontline
therapies [14-18]. As initial therapy, Thalidomide1Department of Stem Cell Transplantation and Cellular
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methasone alone [16]. How these agents integrate with
autologous stem cell transplantation (ASCT), a stan-
dard therapy that improves survival [19-22], is being
studied extensively, especially with regard to their im-
pact on stem cell collection, a necessary step in the
transplantation process.
Stem cell mobilization, or release of hematopoietic
stem cells from the bone marrow (BM) to the periph-
eral blood (PB) in response to cytokines or chemo-
therapy, is dependent on several factors. These
include patient age, BM reserve, mobilizing regimen,
and prior therapy [23-25]. Melphalan (Mel) use before
stem cell collection has been associated with poor stem
cell yield and mobilization failure [26]; therefore, it is
not used as first-line therapy in patients who are candi-
dates for autologous transplantation. Recently, con-
cern has been raised about lenalidomide’s tendency
to similarly decrease stem cell yield and increase the
mobilization failure rate [27-29]. Lenalidomide is
myelosuppressive and alters stromal milieu, and may
indeed suppress stem cell mobilization. To confirm
the hypothesis that lenalidomide impairs stem cell
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mide use on stem cell mobilization and collection with
filgrastim. We also looked at other factors besides
prior lenalidomide that affected mobilization out-
come, and whether remobilization attempts were suc-
cessful in cases in which the first mobilization attempt
failed.PATIENTS AND METHODS
Included in this retrospective study were all
patients with MM referred to the Department of
Stem Cell Transplantation and Cellular Therapy at
The University of Texas M.D. Anderson Cancer
Center, between January 2005 and October 2007,
who underwent stem cell mobilization with
filgrastim. Detailed information about demographics,
disease isotype, stage, prior treatment, interval from
diagnosis, premobilization blood counts, and bone
marrow cellularity was obtained from the departmental
database and chart review. Data were updated and
analyzed in January 2008. Permission for this retro-
spective review was obtained from the institutional
review board.
Of the 354 patients withMMmobilized during this
period, 302 patients underwent mobilization with fil-
grastim and are included in this study. Excluded were
52 patients who underwent mobilization with alterna-
tive strategies: Chemotherapy and filgrastim (n 5 40),
plerixafor plus filgrastrim (n 5 4), and pegfilgrastim
(n 5 8). Chemotherapy was used at the discretion of
the treating physician if the patient had disease that
was unresponsive to previous therapy; 2 of 40 patients
received cyclophosphamide (Cy), and the remaining
38 of 40 received CVAD (Cy, vincristine, doxorubicin,
dexamethasone).Leukapheresis
Patients received filgrastim at a dose of 10 mg/kg/
day until completion of stem cell collection. Dose
was adjusted at the discretion of the apheresis physi-
cian if the PB CD34 count or stem cell yield were sub-
optimal. Counts of PB circulating CD341 progenitor
cells were checked, and leukapheresis was started
when the PB CD341 count exceeded 0.010  109/L.
All patients underwent leukapheresis using the
COBE Spectra cell separator (COBE BCT, Inc.,
Lakewood, CO). Three times the estimated blood vol-
ume was processed during each collection. Standard
citrate dextrose solution was used as an anticoagulant.
Daily leukapheresis was performed until the target cell
doses reached at least 6  106 CD341 cells/kg for pa-
tients who were to undergo tandem transplantation
and reached at least 3  106/kg for patients who
were to undergo a single transplantation procedure.If the collected CD341 cell dose was\0.5  106/kg/
day on 2 consecutive days, the apheresis was stopped.Statistical Analysis
Mobilization failure was defined as the inability to
collect at least 2  106 CD341 cells/kg in 4 leukaphe-
resis procedures. Risk factors predicting mobilization
failure were determined using logistic regression anal-
ysis. Factors studied in univariate analysis included
age, number of prior treatment regimens, prior radia-
tion therapy, interval between diagnosis and mobiliza-
tion, white cell count, platelet count, BM cellularity,
and prior lenalidomide treatment. Factors significant
at a value of P 5 .05 or less were evaluated in a multi-
variate model.RESULTS
Patient Characteristics
During the study period, 302 patients withMMun-
derwent stem cell mobilization with filgrastim at our
institution. Their median age was 58.5 years (range:
31-76 years). There were 185 men and 117 women.
The majority of patients, 186 (62%), had received
only 1 previous treatment regimen. Likewise, a major-
ity of patients, 237 (78%), underwent mobilization
within 12months of diagnosis (Table 1). Lenalidomide
was stopped at a median of 17.5 days (range: 1-211
days) prior to initiation of filgrastim for mobilization.Mobilization Failures
In 26 (9%) of 302 patients, mobilization of stem
cells failed. Significant predictors of mobilization fail-
ure on univariate analysis (Table 2) included more
than 1 prior chemotherapy regimens (P5 .004), an in-
terval of more than 1 year after diagnosis of MM (P\
.001), prior use of lenalidomide (P\ .001), and trans-
plants received in the year 2007 (P 5 .02). The failure
rate (Figure 1) significantly increased in 2007 (14%)
compared with rates in 2006 (5%) and 2005 (7%).
In a multivariate analysis evaluating the indepen-
dent effects of these factors, only, prior lenalidomide
use and stem cell mobilization more than 1 year after
diagnosis of MM remained significant (P \ .001),
with odds ratios of 5.9 (95% confidence interval [CI],
2.4-14.3) and 4.6 (95% CI, 1.9-11.1), respectively
(Table 2).
It is noteworthy that the year was no longer signif-
icant on multivariate analysis. This was likely because
higher proportion of patients in 2007 had pretrans-
plant lenalidomide compared with previous years;
45% of 98 patients seen in 2007 had received premobi-
lization lenalidomide compared to 11% of 204 patients
in previous years.
Table 1. Patient Characteristics (n 5 302)
Characteristic Number (%)
Age
Median (range) 58.5 (38-76)
Sex
Men 185 (61)
Women 117 (39)
Isotype
IgG 177 (59)
IgA 63 (21)
Light chain only 47 (15)
Other (IgD, IgM, Nonsecretory) 15 (5)
Durie-Salmon stage at diagnosis
I 59 (20)
II 127 (42)
III 103 (34)
Unknown 13 (4)
No. of previous treatment regimens
1 186 (62)
>1 115 (38)
Interval from diagnosis to mobilization
#12 months 237 (78)
>12 months 65 (22)
Prior lenalidomide
Yes 64 (21)
No 238 (79)
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We performed a univariate subgroup analysis to
identify patients at high risk of mobilization failure
among those who received and those who did not
receive lenalidomide. The interval between diagnosis
and mobilization was the only significant predictor of
failure in both subgroups. In addition, in patients
who were previously treated with lenalidomide, .3
cycles of lenalidomide (P 5 .001), and .1 prior treat-
ment regimen (P 5 .04) were associated with signifi-
cantly higher risk. Mobilization failed in 78% of
patients (7 of 9) who received .3 cycles of lenalido-
mide, compared with 16% of patients (9 of 55) who
received 1 to 3 cycles of lenalidomide. It is noteworthy
that the interval between the last day of lenalidomide
therapy and filgrastim initiation did not significantly
affect the success rate of stem cell mobilization. In
addition, our data showed a trend for higher risk of
failure for older patients (P 5 .05) who had received
lenalidomide. Because of sample size limitations we
could not perform a multivariate analysis to evaluate
the independent effects of the interval since diagnosis,
number of prior chemotherapy regimens, number of
lenalidomide cycles, and age in the subgroup of pa-
tients who had received lenalidomide.Remobilization
The majority of patients in whom mobilization
failed, including those who received lenalidomide,
successfully underwent remobilization with chemo-
therapy. Remobilization with chemotherapy and fil-
grastim was attempted in 21 of 26 patients for whom
mobilization failed on the first attempt. Chemotherapyregimens used included CVAD in 16 patients, Cy
alone in 4 patients, and ifosfamide plus etoposide in
1 patient. Remobilization was successful in 18 (86%)
of 21 patients; a median of 7  106 CD341 cells/kg
(range: 2.2-15  106 CD341 cells/kg) was collected.
This group included 10 (77%) of 13 patients who
had previously received lenalidomide. All patients un-
derwent autologous transplantation. Times to neutro-
phil and platelet engraftment were similar to those for
the patients whose stem cells mobilized on the first
attempt with filgrastim alone (data not shown). Two
patients for whom\2 106 CD341 cells/kg were col-
lected in 4 leukapheresis procedures underwent addi-
tional leukapheresis, and adequate doses of stem cells
were collected after a total of 7 procedures in 1 patient
and 8 procedures in the other. One patient underwent
BM harvest. Repeat mobilization was not attempted in
2 patients.
Outcome of Patients Mobilized with Alternative
Strategies
Thirty-nine of 40 patients given chemotherapy,
and filgrastim were successfully mobilized, with a me-
dian yield of 13.2 106 CD341 cells/kg (range: 2.1-70
 106 CD341 cells/kg). This included 12 patients who
had previously received lenalidomide. One patient
died prior to stem cell collection. All 4 patients who
received plerixafor and filgrastim and 7 of 8 patients
mobilized with Peg filgrastim were successfully
collected; none of these 12 patients had received lena-
lidomide previously.DISCUSSION
In this study, we suggest that lenalidomide use
before transplantation impairs stem cell mobilization
in response to filgrastim, but this effect is overcome
by using chemotherapy and filgrastim. Mobilization
with filgrastim failed in 25% of patients who had pre-
viously received lenalidomide, compared with 4% of
patients who had not. In the majority of these patients
(77%), remobilization with chemotherapy and filgras-
tim was successful, and these patients could success-
fully undergo ASCT.
Although our study is limited by its retrospective
nature, several lines of reasoning support our conclu-
sions. It could be argued that biases inherent in this
design may explain our findings and that patients
who received lenalidomide had advanced disease,
and therefore were more susceptible to mobilization
failure. However, this conclusion was not supported
by the persistence of a significant lenalidomide effect
after adjusting for the number of prior chemotherapy
regimens in multivariate analysis. Among patients
who had previously received only 1 chemotherapy
regimen, a significantly higher mobilization failure
Table 2. Risk Factors Predicting Mobilization Failure*
Univariate Analysis Multivariate Analysis
N N failed % failed OR 95% CI P OR 95% CI P
Total 302 26 9%
Age
#60 years 171 11 6%
>60 years 131 15 11% 1.9 0.8-4.2 .13
Prior chemo regimens
#1 186 9 5%
>1 115 17 15% 3.4 1.5-7.9 .004
Previous radiation
Yes 90 9 10% 1.3 0.5-2.9 .6
No 212 17 8%
Interval between diagnosis and mobilization
#12 months 237 11 5%
>12 months 65 15 23% 6.1 2.7-14 <.001 4.6 1.9-11.1 .001
White blood cell count (109/Liter)
#4 41 6 15%
>4 260 20 8% 0.5 0.2-1.3 .15
#5.7 (median) 152 17 11%
>5.7 149 9 6% 0.5 0.2-1.2 .1
Platelet count (109/Liter)
#262 (median) 150 17 11%
>262 151 9 6% 0.5 0.2-1.1 .1
#150 24 3 12%
>150 277 23 8% 0.6 0.2-2.3 .5
Cellularity
#30% 137 11 8%
>30% 164 14 8% 1.1 0.5-2.4 .9
#35% (median) 159 13 8%
>35% 142 12 8% 1 0.5-2.3 .9
Prior lenalidomide
No 238 10 4%
Yes 64 16 25% 7.6 3.2-18 <.001 5.9 2.4-14.3 <.001
Year
2005 67 5 7%
2006 137 7 5%
2007 98 14 14% 2.7 1.2-6 .02
*Totals vary because of unknown values of some characteristics for 1 patient.
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Figure 1. Mobilization failure rate by calendar year with and without
prior lenalidomide (len). (No patient received lenalidomide in 2005.)
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part of that regimen (13%) than was seen in patients
who had not received lenalidomide (3%). In fact,
higher failure rates were seen in all subgroups of
patients who received lenalidomide (Table 3). More-
over, the higher the number of courses of lenalido-
mide, the higher the failure rate; the failure rate was
78% in patients who had more than 3 courses of lena-
lidomide, compared with 16% in patients who re-
ceived 3 courses or less.
Further supporting our findings are other reports
of lower stem cell yields and increased mobilization
failure rates in patients who had received prior lenali-
domide [27-29]. Kumar et al. [27] reported a significant
decrease in stem cell yield in patients who had been
previously treated with lenalidomide compared with
those who had not received it beforehand; moreover,
among all patients who underwent mobilization with
filgrastrim, stem cells could not be collected in 3
(7%) of 43 patients who had previously received lena-
lidomide, compared with only 2 (1%) of 199 who had
not received lenalidomide. All 3 lenalidomide-treated
patients in whom mobilization failed had receivedmore than 6 months of this agent. Although confirm-
ing the trend of impaired stem cell mobilization after
lenalidomide, the study of Kumar and colleagues [27]
had a lower failure rate than did our study, possibly be-
cause Kumar et al. included only patients who were
within 12months of diagnosis. In our study, an interval
Table 3. Risk Factors Predicting Mobilization Failure in Patients Who Received and Those Who Did Not Receive Lenalidomide
Lenalidomide Used Lenalidomide Not Used
N N Failed % Failed P N N Failed % Failed P
64 16 25% 238 10 4%
Age
#60 years 34 5 15% 137 6 4%
>60 years 30 11 37% .05 101 4 4% .9
Prior chemo regimens
#1 31 4 13% 155 5 3%
>1 33 12 36% .04 82 5 6% .3
Previous radiation
Yes 24 5 21% 66 4 6%
No 40 11 28% .5 172 6 3% .4
Interval between
diagnosis and mobilization
#12 months 40 6 15% 197 5 3%
>12 months 24 10 42% .02 41 5 12% .01
White blood cell count
(109/Liter)
#4 14 3 21% 27 3 11%
>4 50 13 26% .7 210 7 3% .07
#5.7 (median) 38 9 24% 114 8 7%
>5.7 26 7 27% .8 123 2 2% .06
Platelet count (109/Liter)
#262 (median) 36 11 31% 114 6 5%
>262 28 5 18% .2 123 4 3% .4
#150 8 2 25% 16 1 6%
>150 56 14 25% .9 221 9 4% .7
Cellularity
#30% 27 6 22% 110 5 5%
>30% 36 9 25% .8 128 5 4% .8
#35% (med) 32 8 25% 127 5 4%
>35% 31 7 23% .8 111 5 5% .8
Lenalidomide cycles
1-3 55 9 16% NA NA NA
>3 9 7 78% .001 NA NA NA
Interval between stopping
lenalidomide and mobilization
#9 days 18 5 28% NA NA NA
10-17 days 15 4 27% .9 NA NA NA
18-46 days 13 2 15% .4 NA NA NA
>46 days 17 4 24% .8
722 Biol Blood Marrow Transplant 15:718-723, 2009U. Popat et al.of.12months between diagnosis of myeloma and col-
lection of stem cells was a significant (P\ .001) factor
in predicting mobilization failure, a finding that has
previously been documented as well [25].
Results of 2 other small case series [28,29] are in
agreement with our findings. The first showed a mobi-
lization failure rate of 45% in 20 lenalidomide-treated
patients, compared with a rate of 7% in 41 patients
who had not received lenalidomide. The second study
showed a failure rate of 43% in 28 patients previously
treated with lenalidomide. As in our study described
here, stem cell remobilization in these patients was
successfully induced with chemotherapy and filgras-
tim. The failure rate of 43%-45% observed in these
studies is higher then the rate of 25% observed in the
current study. It is possible that this may be because
of differing patient characteristics. But it is also
possible that because of the design of our study, we
may have underestimated the incidence of mobiliza-
tion failure. Patients were mobilized with filgrastim
or chemotherapy at the discretion of their treatingphysicians. Patients with high disease burden who
had failed previous treatments were more likely to be
mobilized with chemotherapy. Likewise, the realiza-
tion of increased failure rate with filgrastim may have
prompted upfront use of chemotherapy to mobilize
stem cells in some of the patients who had previously
received lenalidomide in the later period of the study.
Our study includes a large number of patients who
were treated similarly at a single institution over a short
period of time, so it provides the necessary power for
identifying potential risk factors for mobilization fail-
ure. What this study does not do is provide a reason
or amechanism that explains the effect of lenalidomide
on stem cell trafficking.
The role of prior Mel therapy in impairing subse-
quent stem cell collection has been well known, and
frontline use of this agent is discouraged in patients
who are suitable candidates for autologous transplanta-
tion [26]. The implications of this finding for lenalido-
mide are more uncertain, particularly because it is such
an active agent, with a response rate of more than 90%
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be collected within 6 months of starting lenalidomide
[27]. Our data, however, indicate that the failure rate
is very high (78%) if patients have received .3 cycles
of this therapy. Mobilization with chemotherapy and
filgrastim rather than filgrastim alonemight be consid-
ered in patients receiving .3 cycles of lenalidomide
prior to mobilization. Certainly, for patients in whom
a first mobilization attempt with filgrastim fails, it
would be reasonable to make a second mobilization
attempt with chemotherapy and filgrastim, a strategy
that was successful in more than three-quarters of our
patients. The impact of newer mobilizing agents such
as plerixafor for initial mobilization or remobilization
in patients who have previously received lenalidomide
is uncertain and needs to be studied.
To conclude, lenalidomide hampers subsequent
stem cell mobilization and collection with filgrastim,
and remobilization with chemotherapy and filgrastim
is successful in most patients in whom stem cell mobi-
lization with filgrastim alone has failed. The mecha-
nism for this effect largely remains speculative and
will certainly be a subject of further studies. This study
does, however, have significant implications for how
we should integrate this highly effective drug within
our therapeutic armamentarium against MM.ACKNOWLEDGMENTS
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